Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing